Management of immune thrombocytopenia - something old, something new.
N Engl J Med. 2010 Nov 11;363(20):1959-61
Authors: George JN
For most of my career, the management of immune thrombocytopenia has evolved from clinical experience rather than clinical evidence. When I was a medical student at Ohio State University in 1960, my mentors were shifting their initial treatment for immune thrombocytopenia from splenectomy to the recently available glucocorticoids.(1) Over the next 40 years, although multiple other treatments were reported in case series of selected patients, glucocorticoids and splenectomy remained the most common first and second treatments, respectively, for immune thrombocytopenia. When a guideline for immune thrombocytopenia was developed by the American Society of Hematology in 1996,(2) there was little clinical-trial . . .
PMID: 21067388 [PubMed - in process]